Diane M. Biskobing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Diane M. Biskobing has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Angela M. Novy
1 shared publicationRobert Downs
1 shared publication
Latest Publications
- 30 November 2003
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 14 (9) , 396-397
Focus on replacement therapy: Endocrine Replacement Therapy in Clinical Practice edited by A. Wayne Meikle. Humana, 2003. US$145.00 (xi+549 pages) ISBN 1 58829 195 2
- 30 November 2003
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 14 (9) , 396-397
Focus on replacement therapy: Endocrine Replacement Therapy in Clinical Practice edited by A. Wayne Meikle. Humana, 2003. US$145.00 (xi+549 pages) ISBN 1 58829 195 2
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 447-452
Novel therapeutic options for osteoporosis
Osteoporosis remains a significant clinical problem despite effective therapies. Many patients cannot or will not take currently available therapies. For this reason, research continues in search of more effective and more tolerable agents. Arzoxifene and TSE-424 are investigational selective estrogen receptor modulators that have been shown to be effective in animal studies and are now in clinical studies. Tibolone is a tissue-specific steroid that is currently used in Europe for the prevention and treatment of osteoporosis. Multiple studies have shown efficacy in improving bone mineral density, but no fracture studies have been conducted to date. Although studies of the effect of isoflavones on bone mineral density have been encouraging, a large multicenter study in Europe recently showed no effect of isoflavones on fractures. The investigational bisphosphonates ibandronate and zoledronic acid may offer the advantage of less frequent dosing. The newly described agent osteoprotegerin has been shown in early studies to inhibit bone turnover. Finally, the issue of efficacy of statins in bone continues to be debated with no prospective, randomized studies yet to confirm the suggestion of benefit seen in epidemiologic studies.
- 1 July 2002
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 14 (4) , 447-452
Novel therapeutic options for osteoporosis
Osteoporosis remains a significant clinical problem despite effective therapies. Many patients cannot or will not take currently available therapies. For this reason, research continues in search of more effective and more tolerable agents. Arzoxifene and TSE-424 are investigational selective estrogen receptor modulators that have been shown to be effective in animal studies and are now in clinical studies. Tibolone is a tissue-specific steroid that is currently used in Europe for the prevention and treatment of osteoporosis. Multiple studies have shown efficacy in improving bone mineral density, but no fracture studies have been conducted to date. Although studies of the effect of isoflavones on bone mineral density have been encouraging, a large multicenter study in Europe recently showed no effect of isoflavones on fractures. The investigational bisphosphonates ibandronate and zoledronic acid may offer the advantage of less frequent dosing. The newly described agent osteoprotegerin has been shown in early studies to inhibit bone turnover. Finally, the issue of efficacy of statins in bone continues to be debated with no prospective, randomized studies yet to confirm the suggestion of benefit seen in epidemiologic studies.